Management of Bleeding and Hemolysis During Percutaneous Microaxial Flow Pump Support: A Practical Approach

JACC Cardiovasc Interv. 2023 Jul 24;16(14):1707-1720. doi: 10.1016/j.jcin.2023.05.043.

Abstract

Percutaneous ventricular assist devices (pVADs) are increasingly being used because of improved experience and availability. The Impella (Abiomed), a percutaneous microaxial, continuous-flow, short-term ventricular assist device, requires meticulous postimplantation management to avoid the 2 most frequent complications, namely, bleeding and hemolysis. A standardized approach to the prevention, detection, and treatment of these complications is mandatory to improve outcomes. The risk for hemolysis is mostly influenced by pump instability, resulting from patient- or device-related factors. Upfront echocardiographic assessment, frequent monitoring, and prompt intervention are essential. The precarious hemostatic balance during pVAD support results from the combination of a procoagulant state, due to critical illness and contact pathway activation, together with a variety of factors aggravating bleeding risk. Preventive strategies and appropriate management, adapted to the impact of the bleeding, are crucial. This review offers a guide to physicians to tackle these device-related complications in this critically ill pVAD-supported patient population.

Keywords: bleeding; hemolysis; management; pVAD.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Heart-Assist Devices* / adverse effects
  • Hemolysis
  • Hemorrhage / diagnostic imaging
  • Hemorrhage / etiology
  • Hemorrhage / prevention & control
  • Humans
  • Percutaneous Coronary Intervention* / adverse effects
  • Shock, Cardiogenic
  • Treatment Outcome